Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?

Journal article

Peer reviewed

Morgan H James, Jennifer E Fragale, R Nisha Aurora, Nina A Cooperman, Daniel D Langleben and Gary Aston-Jones

Neuropsychopharmacology (New York, N.Y.), Vol.45(5), pp.717-719

04/2020

PMID: 31986520

Abstract

Triazoles - administration & dosage

Opioid-Related Disorders - drug therapy

Animals

Orexin Receptor Antagonists - therapeutic use

Craving - drug effects

Humans

Orexin Receptor Antagonists - administration & dosage

Drug Repositioning

Azepines - administration & dosage

Azepines - therapeutic use

Triazoles - therapeutic use

24 Record Views

Title: Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?
Creators: Morgan H James - Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
Jennifer E Fragale - Brain Health Institute, Rutgers University, Piscataway, NJ, USA
R Nisha Aurora - Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Nina A Cooperman - Division of Addiction Psychiatry, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
Daniel D Langleben - Philadelphia VA Medical Center, Philadelphia, PA, USA
Gary Aston-Jones - Brain Health Institute, Rutgers University, Piscataway, NJ, USA. aston.jones@rutgers.edu
Publication Details: Neuropsychopharmacology (New York, N.Y.), Vol.45(5), pp.717-719
Date published: 04/2020
Grant note: R21 DA043983 / NIDA NIH HHS K12 GM093854 / NIGMS NIH HHS R01 DA006214 / NIDA NIH HHS R33 AT010109 / NCCIH NIH HHS K99 DA045765 / NIDA NIH HHS K23 HL118414 / NHLBI NIH HHS
Academic Unit: Brain Health Institute; Psychiatry - Integrated Mental Health Services (RWJMS); Psychiatry - CAB (RWJMS)
Language: English
Resource Type: Journal article
Identifiers: 991031654731504646